1. |
- Antfolk, Christian, et al.
(author)
-
Sensory feedback in upper limb prosthetics.
- 2013
-
In: Expert Review of Medical Devices. - : Informa UK Limited. - 1745-2422 .- 1743-4440. ; 10:1, s. 45-54
-
Journal article (peer-reviewed)abstract
- One of the challenges facing prosthetic designers and engineers is to restore the missing sensory function inherit to hand amputation. Several different techniques can be employed to provide amputees with sensory feedback: sensory substitution methods where the recorded stimulus is not only transferred to the amputee, but also translated to a different modality (modality-matched feedback), which transfers the stimulus without translation and direct neural stimulation, which interacts directly with peripheral afferent nerves. This paper presents an overview of the principal works and devices employed to provide upper limb amputees with sensory feedback. The focus is on sensory substitution and modality matched feedback; the principal features, advantages and disadvantages of the different methods are presented.
|
|
2. |
|
|
3. |
- Dahlgren, Jovanna, 1964
(author)
-
Easypod: a new electronic injection device for growth hormone
- 2008
-
In: Expert Review of Medical Devices. - : Informa UK Limited. - 1743-4440 .- 1745-2422. ; 5:3, s. 297-304
-
Journal article (peer-reviewed)abstract
- The easypod is the first automated electronic injection device for growth hormone delivery. To save user's time and reduce administration error, the dose is preset by a physician or nurse; in addition, to allow patient adherence to be monitored, the time, date and dose (mg) of each injection is recorded. Details of the last injection and number of doses remaining in the cartridge are also displayed in order to help patients manage the injection schedule. Drug use can be optimized by splitting the dose over two cartridges, with an automatic compensation facility to avoid under-dosing. Patients can customize the depth, speed and duration of the injection. In a user trial, easypod was very well accepted. This review places easypod in the context of current and future growth hormone devices.
|
|
4. |
- D’Oria, Mario, et al.
(author)
-
Novel insights into thoracic endografts technology for prevention of distal stent-graft induced new entry (dSINE) following endovascular repair of type B aortic dissections : from bench to bedside
- 2024
-
In: Expert Review of Medical Devices. - : Taylor & Francis. - 1743-4440 .- 1745-2422. ; 21:5, s. 391-398
-
Research review (peer-reviewed)abstract
- Introduction: Endovascular treatment of type B aortic dissections (TBAD) has currently acquired a primary therapeutic role when anatomically feasible. The main issue with thoracic endovascular aortic repair (TEVAR) for aortic dissection is the actual nature of the aortic wall, which is structurally compromised and more fragile. Indeed, a wealth of data have shown that TEVAR for TBAD will lead, in a substantial proportion of cases, to a device-related adverse event named distal stent-graft induced new entry (dSINE).Areas Covered: Currently available aortic stent-grafts have not been specifically devised for the treatment of aortic dissection. A novel dissection specific stent-graft (DSSG) was developed, which is a custom-made device based on the Zenith Alpha Thoracic platform (Cook Medical). The DSSG has several unique properties that, in principle, make its use optimal in TBAD patients.Expert Opinion: TEVAR in the setting of aortic dissections remains technically challenging. The occurrence of dSINE represents a unique complication in this scenario and may lead to high rates of aortic-related adverse events and need for secondary interventions. The use of a novel custom-made DSSG in the setting of chronic TBAD has been proven to be safe, feasible and effective. However, even this approach may fail to completely prevent dSINE formation.
|
|
5. |
|
|
6. |
|
|
7. |
|
|
8. |
- Kempe, Henrik, et al.
(author)
-
Nanomedicine’s promising therapy: magnetic drug targeting
- 2011
-
In: Expert Review of Medical Devices. - : Informa UK Limited. - 1745-2422 .- 1743-4440. ; 8:3, s. 291-294
-
Journal article (peer-reviewed)abstract
- Magnetic drug targeting is a promising therapy that can benefit patients, as well as provide novel opportunities for pharmaceutical and medical technology/device industries.
|
|
9. |
- Lagali, Neil, et al.
(author)
-
Editorial Material: Biosynthetic corneas: prospects for supplementing the human donor cornea supply in EXPERT REVIEW OF MEDICAL DEVICES, vol 8, issue 2, pp 127-130
- 2011
-
In: Expert Review of Medical Devices. - : EXPERT REVIEWS, UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND. - 1743-4440 .- 1745-2422. ; 8:2, s. 127-130
-
Journal article (other academic/artistic)abstract
|
|
10. |
- Nilsson, Malin K, et al.
(author)
-
The composite of hydroxyapatite and calcium sulphate: a review of preclinical evaluation and clinical applications.
- 2013
-
In: Expert Review of Medical Devices. - : Informa UK Limited. - 1745-2422 .- 1743-4440. ; 10:5, s. 675-684
-
Research review (peer-reviewed)abstract
- Recent publications have shown that the combination of α-calcium sulfate hemihydrate, the densest form of hydrates and hydroxyapatite (HA) particles gives good clinical outcome in various applications. It has large potential as bone substitute since the material transforms to bone throughout the entire volume and not only by creeping substitution, from the surface toward the inside. Release of important proteins for osteogenesis has been observed around implanted material and is speculated to be due to fast dissolution of the calcium sulfate phase in combination with the osteoconductive and bioactive nature of HA. In diabetic foot infection, the osteoconductive HA/calcium sulfate material has been successfully used loaded with antibiotics and since it is injectable, the application is minimally invasive, easy and precise. It is a bone substitute for the future.
|
|